Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 18INDUSTRY 15NIH 5OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1Breast Diseases 1

Interventions

Bevacizumab 5Capecitabine 3toripalimab 2olaparib 2durvalumab 2darolutamide 2atezolizumab 2apatinib 2anlotinib 2Standard of Care 2Radiotherapy 2Radiosurgery 2Oxaliplatin 2Leucovorin 2Laparoscopy 2Immunotherapy 2Fluorouracil 2Everolimus 2Drug Therapy 2Blood Specimen Collection 2130-nm albumin-bound paclitaxel 2trametinib 1spartalizumab 1pyrotinib 1pomalidomide 1palbociclib 1nilotinib 1ledipasvir, sofosbuvir drug combination 1ledipasvir 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × exemestane × 90 days × Clear all
NCT07581834 2026-05-12

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Fujian Cancer Hospital

Phase 2 Recruiting
2,000 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡